Aptimmune Biologics of Research Park launches PRRSV vaccine

Aptimmune Biologics Inc. recently launched the worlds first commercially available mucosal autogenous PRRSV vaccine for swine, administered via nasal spray. The vaccine was made with BARRICADE formulation technology, which offers a revolutionary approach to PRRSV management. 

Dr. Bob Nordgen, Aptimmune Biologic Consulting Immunologist says, “The intent is to create immunity at the respiratory surface, where the pig is naturally challenged. This vaccine offers a real opportunity to address a significant gap in disease control that still exists years after PRRSV was first identified.” 

For the full story, read here: http://bit.ly/2r0BiBK.